Funding Opportunities

Application due:

• Initial proposal drafts for Domestic Scholars are due 5 January 2018 and full applications are due 19 January 2018
• Initial proposal drafts for International Scholars are due 29 January 2018 and full applications are due 12 February 2018

The HIV Prevention Trials Network (HPTN) is proud to offer two scholarship programs for early-career investigators funded through a supplement from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute on Drug Abuse (NIDA). The HPTN Scholars Program now includes two components: a domestic (U.S.) program and an international program. Both programs seek to increase opportunities for scientists from groups under-represented in HIV prevention research. In the domestic program, successful applicants will be Investigators who have received their terminal degree (MD, Phd, etc). For the international version, current MD, PhD, and MBChB students may apply, along with individuals having already graduated with their terminal degree. In both programs, applicants should desire to work with a mentor scientist in the Network to complete a research project based upon an existing HPTN research study.

https://hptn.org/research/scholars

https://www.vanderbilt.edu/provost/occi/tips.php

Vanderbilt Initiative Awards (ViA):

• Small-scale or new initiatives that showcase potential to become a major hub of activity - center or institute - that will advance the core missions of Vanderbilt
• Provide seed funding up to $100,000 per year.
• Provide faculty the opportunity to pursue innovative ideas for discovery and learning with colleagues from diverse disciplines.
• Must include collaborators from multiple schools and colleges.* 

Vanderbilt Reinvestment Awards (VRA):

• Awarded to existing centers and institutes that facilitate learning collaborations across campus.
• Assist collaborations taking a critical next step in order to ensure continued success.
• Funding varies on a case-by-case basis.
• Must secure partnerships with respective deans as part of the full-proposal submission process.

R01 Application Due Date(s): January 14, 2020, January 14, 2021, and January 14, 2022 by 5:00 PM local time of applicant organization.

R21 Application Due Date(s): January 14, 2020; January 14, 2021, by 5:00 PM local time of applicant organization

This Funding Opportunity Announcement (FOA) encourages innovative, high risk, high impact research to investigate the innate and/or adaptive immune responses induced by mycobacterial infections, Bacillus Calmette-Guérin vaccine (BCG) and/or candidate Mycobacterium tuberculosis (Mtb) vaccines in HIV-infected or uninfected individuals. Studies that will provide insights into the immune mechanisms required for protection from Mtb infection/re-infection or progression to active disease in latently infected individuals are encouraged. This research is expected to provide data to advance new hypotheses on immune mechanisms that contribute to the advancement of new tuberculosis (TB) vaccines, including in populations also infected with HIV.

R01: https://grants.nih.gov/grants/guide/pa-files/PAR-19-307.html

R21: https://grants.nih.gov/grants/guide/pa-files/PAR-18-923.html

Application Due Dates: Standard dates/ AIDS dates apply, by 5:00 PM local time of applicant organization.

This funding opportunity announcement (FOA) calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex.

R01: https://grants.nih.gov/grants/guide/pa-files/PA-18-729.html

R21: https://grants.nih.gov/grants/guide/pa-files/PA-18-728.html